Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

This study is testing TBI-2001, a type of personalized immune cell therapy called CAR-T cell therapy, which takes a patient's own immune cells, genetically engineers them to attack cancer cells, and infuses them back. It targets CD19, a protein found on certain blood cancer cells. The study is for people with relapsed or treatment-resistant B-cell lymphomas, CLL, or SLL. **You may be eligible if...** - You are 18 or older with confirmed CD19-positive B-cell non-Hodgkin lymphoma, CLL, or SLL - You have received at least 2 prior treatments that did not work or stopped working - You are not eligible for or have exhausted other potentially curative treatment options - Your overall health is adequate for the procedure **You may NOT be eligible if...** - You have not received at least 2 prior therapies - You have active brain cancer involvement - You have uncontrolled infections or serious organ failure - You have had certain prior CAR-T therapies (depending on the study cohort) Talk to your doctor to see if this trial is right for you.